Lys49
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys49  -  14-3-3 zeta (human)

Site Information
NLLsVAykNVVGARR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 474726
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 17 , 18 , 19 ) , mass spectrometry (in vitro) ( 1 ) , modification-specific antibody ( 1 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
bone cancer ( 1 ) , gastric cancer ( 13 ) , leukemia ( 18 ) , chronic myelogenous leukemia ( 18 ) , lung cancer ( 2 , 3 , 4 , 5 , 6 , 7 , 8 ) , non-small cell lung cancer ( 3 , 4 , 5 , 6 , 7 , 8 , 11 , 12 , 14 , 15 ) , non-small cell lung adenocarcinoma ( 2 , 3 , 4 , 5 , 6 , 7 , 12 ) , non-small cell large cell lung carcinoma ( 3 , 7 ) , non-small cell squamous cell lung carcinoma ( 2 , 15 ) , ventricular tachycardia ( 17 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 6 , 19 ) , Cal-12T (pulmonary) ( 4 ) , Calu-3 (pulmonary) ( 8 ) , cardiac-heart ( 17 ) , DMS153 (pulmonary) ( 5 ) , HCC15 (pulmonary) ( 2 ) , HCC44 (pulmonary) ( 4 ) , HCC78 (pulmonary) ( 3 ) , HCC827 (pulmonary) ( 8 ) , HEK293T (epithelial) ( 1 ) , HeLa (cervical) ( 9 ) , Jurkat (T lymphocyte) ( 10 , 19 ) , K562 (erythroid) ( 18 ) , LOU-NH91 (squamous) ( 2 ) , lung ( 2 , 3 , 4 , 5 , 6 , 7 , 8 ) , MKN-45 (gastric) ( 13 ) , MV4-11 (macrophage) ( 19 ) , NCI-H1299 (pulmonary) ( 7 ) , NCI-H1355 (pulmonary) ( 6 ) , NCI-H1437 (pulmonary) ( 4 , 5 ) , NCI-H1650 (pulmonary) ( 8 ) , NCI-H1666 (pulmonary) ( 4 ) , NCI-H1703 (squamous) ( 2 , 15 ) , NCI-H1734 (pulmonary) ( 7 ) , NCI-H1781 (pulmonary) ( 3 ) , NCI-H1792 (pulmonary) ( 6 ) , NCI-H1944 (pulmonary) ( 7 ) , NCI-H1975 (pulmonary) ( 8 ) , NCI-H2073 (pulmonary) ( 2 , 5 ) , NCI-H209 (pulmonary) ( 5 ) , NCI-H2106 (pulmonary) ( 8 ) , NCI-H2228 (pulmonary) ( 3 , 12 ) , NCI-H23 (pulmonary) ( 6 ) , NCI-H2342 (pulmonary) ( 2 ) , NCI-H2405 (pulmonary) ( 4 ) , NCI-H3122 (pulmonary) ( 3 , 11 ) , NCI-H3255 (pulmonary) ( 14 ) , NCI-H358 (pulmonary) ( 7 ) , NCI-H441 (pulmonary) ( 6 ) , NCI-H460 (pulmonary) ( 7 ) , NCI-H661 (pulmonary) ( 3 ) , NCI-H838 (pulmonary) ( 5 ) , U2OS (bone cell) ( 1 )

Upstream Regulation
Treatments:
selisistat ( 1 ) , trichostatin_A ( 1 ) , tubacin ( 1 ) , Tubastatin A ( 1 ) , vorinostat ( 1 )

Downstream Regulation
Effects of modification on 14-3-3 zeta:
molecular association, regulation ( 1 )
Effects of modification on biological processes:
apoptosis, induced ( 1 )
Inhibit interaction with:
AS160 (human) ( 1 ) , ATG9A (human) ( 1 ) , BAD (human) ( 1 ) , KIF11 (human) ( 1 )

References 

1

Mortenson JB, et al. (2015) Histone deacetylase 6 (HDAC6) promotes the pro-survival activity of 14-3-3ζ via deacetylation of lysines within the 14-3-3ζ binding pocket. J Biol Chem 290, 12487-96
25770209   Curated Info

2

Rikova K (2013) CST Curation Set: 20218; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

3

Rikova K (2013) CST Curation Set: 20219; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

4

Rikova K (2013) CST Curation Set: 20220; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

5

Rikova K (2013) CST Curation Set: 20221; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

6

Rikova K (2013) CST Curation Set: 20215; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

7

Rikova K (2013) CST Curation Set: 20216; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

8

Rikova K (2013) CST Curation Set: 20217; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

9

Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51
23954790   Curated Info

10

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

11

Rikova K (2013) CST Curation Set: 18855; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

12

Rikova K (2013) CST Curation Set: 18854; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

13

Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

14

Rikova K (2012) CST Curation Set: 16031; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

15

Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

16

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

17

Li Y (2010) CST Curation Set: 10391; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

18

Moritz A (2010) CST Curation Set: 9920; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

19

Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.